Nobel Biocare full year 2013 revenue up 2.2% (CER) with improving underlying profitability
. Revenue for the full year at CER grew 2.2% versus prior year to EUR 566.8 million (-2.4% in EUR), representing the…
. Revenue for the full year at CER grew 2.2% versus prior year to EUR 566.8 million (-2.4% in EUR), representing the…
Year-to-date September 2010: Reported revenue down 0.6% to EUR 423.3 million (CER -5.9%) Sales trend slightly impro…
. - Reported revenue down 6.1% to EUR 581.4 million (CER minus 7.7%); revenues in line with markets - EMEA (excl. Spai…
. - Reported revenue down 6.1% to EUR 581.4 million (CER minus 7.7%); revenues in line with markets - EMEA (excl. Spai…
. - Growth in line with market despite deferred scanner revenues and unfavorable country mix - Reported revenue growth…
. - Revenue growth in Q1 at constant exchange rates (CER) minus 9% at EUR 147.0 million - Reported revenue growth minu…
. - Revenue growth at constant exchange rates (CER) minus 4% at EUR 619.2 million - Change in commercial approach in Q…
. - Revenue growth at constant exchange rates (CER) minus 1% at EUR 456.6 million - Economic environment affected US…
Nobel Biocare (NOBN) announced today that the deteriorating economic environment has adversely affected its sales toward…
. - Revenue growth at constant exchange rates (CER) flat at EUR 323.8 million - Improving sales in US (NA Q2: +3.7%) a…